Orthofix announces first clinical use of Virtuos lyograft autograft substitute

1080
Virtuos lyograft (Orthofix)

Orthofix has announced the limited market release and first patient implant of the Virtuos lyograft, which the company describes as a first-of-its-kind, shelf-stable and complete autograft substitute for spine and orthopaedic procedures.

The allograft is prepared by MTF Biologics through a proprietary process that preserves all biologic components necessary for bone healing within the graft. Virtuos is provided in a room-temperature, ready-to-use, mouldable form.

“The Virtuos allograft is unique in the fact that it can be stored at room temperature and is ready to implant within two minutes of being hydrated,” said Tomas Ellis, a neurosurgeon at Baylor Scott and White Surgical Hospital (Fort Worth, USA), who implanted the first patient. “This helps ensure we can always have an easy-to-use, mouldable, complete bone graft on hand, and it streamlines the preparation and overall surgical procedure time.”

Kevin Kenny, president of global spine at Orthofix, added: “The Virtuos lyograft provided through our exclusive partnership with MTF Biologics is at the forefront of allograft technology.

“Processed through a proprietary preservation method, Virtuos provides the best of both worlds. It delivers a high-quality shelf-stable bone graft with the clinical performance and superior handling that clinicians desire, as well as streamlined logistics for storage and preparation for the hospital.”

According to the company, Virtuos offers significant logistical and cost-savings advantages to the hospital with improved shipping, storage and operating room efficiency. The room temperature shipment and storage of Virtuos eliminates the use of large quantities of dry ice, Styrofoam shippers and freezer storage, enabling flexible shipping options and reduced packaging, with the aim of a reduced carbon footprint, add Orthofix.


LEAVE A REPLY

Please enter your comment!
Please enter your name here